1. Home
  2. XPER vs ACRS Comparison

XPER vs ACRS Comparison

Compare XPER & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Xperi Inc.

XPER

Xperi Inc.

HOLD

Current Price

$5.48

Market Cap

259.7M

Sector

Technology

ML Signal

HOLD

Logo Aclaris Therapeutics Inc.

ACRS

Aclaris Therapeutics Inc.

HOLD

Current Price

$3.54

Market Cap

311.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
XPER
ACRS
Founded
1990
2012
Country
United States
United States
Employees
1460
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
259.7M
311.0M
IPO Year
2021
2015

Fundamental Metrics

Financial Performance
Metric
XPER
ACRS
Price
$5.48
$3.54
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
4
Target Price
$11.00
$9.75
AVG Volume (30 Days)
367.9K
2.5M
Earning Date
05-06-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
69.01
EPS
N/A
N/A
Revenue
$448,105,000.00
$1,683,000.00
Revenue This Year
$4.03
N/A
Revenue Next Year
$8.11
$4.24
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.07
$1.05
52 Week High
$8.24
$4.89

Technical Indicators

Market Signals
Indicator
XPER
ACRS
Relative Strength Index (RSI) 40.99 51.44
Support Level $5.07 $2.67
Resistance Level $6.37 $3.86
Average True Range (ATR) 0.19 0.25
MACD -0.05 -0.01
Stochastic Oscillator 4.41 42.57

Price Performance

Historical Comparison
XPER
ACRS

About XPER Xperi Inc.

Xperi Inc is a media and entertainment technology company. Its technologies are integrated into consumer devices, connected cars, and a variety of media platforms globally, enabling audiences to connect with entertainment content in a more intelligent, immersive, and personal way. As its audiences engage with content on the platform, the company operates a cross-screen advertising solution that enables brands to reach millions of engaged consumers across rapidly expanding digital entertainment ecosystem. It operates in one reportable business segment and group its revenue into four categories: Pay-TV, Consumer Electronics, Connected Car and Media Platform. Geographically it operates in U.S. and Canada, Asia Pacific, Europe, Middle East and Africa, and Other countries.

About ACRS Aclaris Therapeutics Inc.

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.

Share on Social Networks: